Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

A Phase III Study of Atezolizumab Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy [IMvigor010]

Complete title: A Phase III, open-label, multicenter, randomized study of mpdl3280a (anti-pd-l1 antibody) versus observation as adjuvant therapy in patients with pd-l1-selected, high-risk muscle-invasive bladder cancer after cystectomy

Research Study Number 20151596
Principal Investigator Michael Schweizer
Phase III

Research Study Description

This study is to evaluate the efficacy and safety of adjuvant treatment with Atezolizumab compared with observation in participants with PD-L1-selected muscle-invasive bladder cancer (MIBC) who are at high risk for recurrence following cystectomy.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number 20151596
Contact Seattle Cancer Care Alliance Intake Office
Telephone 800-804-8824 / 206-606-1024

Keywords: Bladder Cancer; Solid Tumors; Urogenital Neoplasms; Urologic Neoplasms; Immunotherapy; Urinary Bladder Neoplasms

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials